Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch
I'm PortAI, I can summarize articles.
Wolwo Pharma announced that it has completed the clinical trial of the "Artemisia Annua Pollen Allergen Sublingual Drops." The summary report indicates that the product has good safety in adult patients with allergic rhinitis, with the main adverse reactions being grade 1 and 2. After 2 years of treatment and monitoring after discontinuation, it has been confirmed that the drug effectively improves symptoms caused by Artemisia Annua/Artemisia Pollen and reduces the use of symptomatic medications, providing evidence for long-term clinical application
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments